US/UK/Canada

Share

Pick a time period -
Tags ( Active)

OV A/S establish a flexible loan facility of up to SEK 40 million

Hoersholm, Denmark, August 31, 2018 – Oncology Venture Sweden AB (OV:ST),  a leading biotech company focused on the development of precision medicine using its Drug Response Prediction technology (DRP®) to track , match and treat cancer patients, announced today that Oncology Venture A/S, the merged company - between Oncology Venture Sweden AB and Oncology Venture A/S (previously Medical Prognosis Institute A/S) has entered into a flexible loan agreement with Trention AB. Under the terms of the agreement, Trention has committed to provide up to SEK 40 million in cash to Oncology Venture A/S.

US FDA approves Oncology Venture’s IDE and IND for a clinical trial in ovarian cancer patients with its PARP inhibitor and biomarker 2X-121 DRP

Hoersholm, Denmark, August 27, 2018 – Oncology Venture AB (OV:ST) (“OV” or the “Company”), Oncology Venture US and Medical Prognosis Institute (MPI.ST) today announced that the US Food and Drug Administration (FDA) has accepted its Investigational Device Exemption (IDE) and its Investigational New Drug Application (IND) to begin a Phase 2 clinical trial in advanced ovarian cancer with 2X-121 -a PARP inhibitor- using it’s Drug Response Predictor – DRP® – to select patients with high likelihood of responding to the treatment.   The 2X-121 DRP has a gene signature consisting of more than 400

Registration of merger, de-listing of Oncology Venture from Spotlight Stock Market, last day of trading and record date for the merger

Hoersholm, Denmark, August 24, 2018 – Oncology Venture Sweden AB (“OV”) and Medical Prognosis Institute A/S (now Oncology Venture A/S) (the “Company”) hereby announce, as part of the completion of the previously announced merger between the two companies, that the merger has been registered with the Danish Business Authority and that the Danish Business Authority has notified the Swedish Companies Registration Office (Sw. Bolagsverket) that the legal effects of the merger have commenced. As part of the registration of the merger, the share capital in the Company has been increased to

OV predicts drug efficacy in breast cancer patients. New study on cornerstone drug epirubicin published in “Breast Cancer Research and Treatment”

Hoersholm, Denmark, August 14, 2018 – Oncology Venture Sweden AB (“Oncology Venture”) today announced the publication of the scientific article “Predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort: a retrospective-prospective blinded study” in the peer reviewed scientific journal: Breast Cancer Research and Treatment. The Drug Response Predictor (DRP) is OV’s technology for personalized and precision medicine.  The DRP was significantly associated to its primary endpoint Time to Progression (TTP) in a

MPI has now executed transfer of the last tranche of the Oncology Venture shares sold during May

Medical Prognosis Institute A/S (”MPI”) hereby announces that the last tranche of its holdings in Oncology Venture Sweden AB (”Oncology Venture”) is now transferred. As earlier announced MPI has as part of the merger capitalized it’s shareholding in Oncology Venture. The sale of the shares was announced in May 31, 2018. The last tranche of the sold shares (662,038) is now being transferred to the new owners. Please note that Peter Buhl Jensen will - as the CEO on behalf of MPI - be noted as the responsible person for the sale. For further information, please contact   Ulla Hald Buhl,

Strong LiPlaCis Treatment Results in DRP-Selected Breast Cancer Patients Collaborative LiPlaCis Regulatory Meeting with DKMA

Oncology Venture Provides Clinical and Business Update Hoersholm, Denmark, 02 July 2018 – Oncology Venture Sweden AB (SPOTLIGTH: OV.ST) (“OV” or “the Company”) and MPI announce the third interim report from the ongoing LiPlaCis® Phase 2 study in hard-to-treat metastatic breast cancer patients and outcomes of a recent meeting with the Danish Medicines Agency (DKMA).Regulatory: In this constructive meeting, the Company discussed the interim Phase 2 LiPlaCis data with the DKMA along with a proposed design of a pivotal (i.e. aimed for marketing approval) randomized trial of LiPlaCis for

Oncology Venture looks forward to publishing a clinical update on July 2

Hoersholm, Denmark, June 29, 2018 – Oncology Venture Sweden AB (OV:ST) and Medical Prognosis Institute A/S (MPI:ST) intends, on a quarterly basis, to publish clinical updates regarding the company’s ongoing projects and activities. Oncology Venture looks forward to publishing the first of these updates through a press release on Monday  July 2, 2018 after 12 o’clock.For further information, please contact   Ulla Hald Buhl, COO Or      Peter Buhl Jensen, CEO  Mobile: +45 21 60and  Chief IR & 89 22  E-mail:Communications  Mobile: pbj@

Oncology Venture now holds US Orphan Drug designation on dovitinib for Adenoid Cystic Carcinoma

Hoersholm, Denmark, June 28, 2018 – Oncology Venture AB (OV:ST) and Medical Prognosis Institute A/S (MPI:ST) announces that the Office of Orphan Products Development at the FDA has transferred the Dovitinib Orphan drug designation for the treatment of adenoid cystic carcinoma to Oncology Venture from Novartis.Dovitinib is an oral available phase 3 multi Tyrosine Kinase Inhibitor (previously TKI258), for which OV holds the exclusive global rights for development and commercialization. OV is developing the dovitinib Drug Response predictor DRP® based on existing data from patient’s biopsies

First Patient dosed in Phase 2 Study of the PARP Inhibitor 2X-121 for Breast Cancer

Hoersholm, Denmark, June 26, 2018 – Oncology Venture AB (OV:ST), Oncology Venture US Inc. (former 2X Oncology, Inc.) and Medical Prognosis Institute A/S (MPI:ST) announces dosing of the first patient in a Phase 2 clinical study to investigate the anti-tumor effect and tolerability of 2X-121 in patients with metastatic breast cancer selected by a novel drug response predictor (DRP®) mRNA driven multiple biomarker, the 2X-121 DRP®.2X-121 is a PARP inhibitor. This clinical trial will enroll metastatic Breast Cancer patients, who have relapsed on two or more different prior therapies. The 2X-

MPI and Oncology Venture are merging – here are answers to When, How, and What

Hoersholm, Denmark, June 13, 2018 – Oncology Venture AB (OV:ST) (“OV” or the “Company”) and Medical Prognosis Institute (MPI.ST) (“MPI”) today informed about details regarding the merger between MPI and Oncology VentureOn the basis of the joint merger plan adopted by the boards of Medical Prognosis Institute A/S (“MPI”) and Oncology Venture Sweden AB (“OV”) on March 9, 2018, General Meetings were held on May 30, 2018 in MPI and OV where it was unanimously decided by the represented shareholders in both companies to approve the merger plan between MPI and OV.Under Swedish law, a compulsory

Edison - an Investment Research Company - has published an update in the coverage of Oncology Venture’s share

If you are interested in following the Edison coverage of the Oncology Venture share – sign up here: link  For further information about Oncology Venture, please contact: Ulla Hald Buhl, COO and Chief IR & or Peter Buhl Jensen, CEOMobile: +45 21 60CommunicationsMobile: +45 2170 89 22E-mail: pbj@oncologyventure.com  1049uhb@oncologyventure.com About Oncology Venture Sweden AB  Oncology Venture Sweden AB is engaged in the research and development of anti-cancer drugs via its wholly owned Danish subsidiary Oncology Venture

OV’s clinical data on PARP inhibitor 2X-121 and response prediction validation to be presented on the world’s largest cancer congress ASCO 2018

Hoersholm, Denmark, June 1, 2018 – Oncology Venture AB (OV:ST) (“OV” or the “Company”) today announced that clinical data on PARP inhibitor 2X-121 and response prediction validation is to be presented on the world’s largest cancer congress ASCO 2018 on June 1st 2018. Oncology Venture in-licensed the active PARP inhibitor E7449 now called 2X-121 from Eisai in Q2 2017 and present clinical data as well as data demonstrating validation of Oncology Ventures novel DRP®s ability to identify the patients who will benefit from 2X-121 therapy. “We are very proud that we can already now present

OV announces prolongation of option to buy back shares in OV SPV2 that holds dovitinib

On May 31, 2018, Oncology Venture Sweden AB ("Oncology Venture") has agreed with Sass & Larsen ApS in OV-SPV2 ApS to prolong the option to buy back shares in OV-SPV2 that holds the dovitinib from Novartis. The option will be prolonged until August 31, 2018. The major investor wishes to maintain an ownership of 15% in OV-SPV2 ApS.Option agreement Sass & Larsen and Oncology Venture has agreed to prolong Oncology Venture’s option to buy back shares in OV-SPV2 ApS. Previously the Oncology Ventures option was to acquire 50% of the shares for 5 million USD before June 1st 2018. The

Interim Report 2018-01-01 – 2018-03-31

The Management Board and Chief Executive Officer of Oncology Venture Sweden AB hereby submit a report for the accounting year 2017. “Oncology Venture Sweden AB” refers to Oncology Venture Sweden AB with corporate identification number 559016-3290. “The Company” or “Oncology Venture” refers to the group, that is Oncology Venture Sweden AB and its subsidiary company Oncology Venture ApS (100% owned by Oncology Venture), 2X Oncology (92% by Oncology Venture) and OV-SPV2 ApS (40% owned by Oncology Venture). Summary of communique on financial report   First quarter (2018-01-01 – 2018-03-31)

Bulletin from the annual shareholders’ meeting on May 30, 2018 in Oncology Venture Sweden AB

Hoersholm, Denmark, May 30, 2018 – Today, on May 30, 2018 an annual shareholders’ meeting was held in Oncology Venture Sweden AB. A summary of the resolutions adopted follows below. All resolutions were adopted with the required majority of votes.Resolution on adoption of accounts and allocation of the company’s result The annual shareholders’ meeting resolved to adopt the profit and loss statement and balance sheet and the group profit and loss statement and the group balance sheet. The annual shareholders’ meeting also resolved to allocate the company’s result in accordance with the

Oncology Venture Announces Abstracts on Three Pipeline Products Selected for 2018 ASCO Clinical Meeting

Phase 1 Study of PARP Inhibitor 2X-121 selected as oral Presentation June 1, 2018Hoersholm, Denmark and Cambridge, MA – May 16, 2018 – Oncology Venture AB (OV:ST) (“OV” or the “Company”) announced today that three abstracts detailing clinical trials of its product candidates have been accepted by the American Society for Clinical Oncology (ASCO) for the 2018 ASCO Clinical Meeting. Notably, Ruth Plummer, MD, PhD, FRCP, will present an abstract describing the first-in-human Phase 1 study of 2X-121, an investigational PARP 1/2 and tankyrase 1/2 inhibitor, as monotherapy in patients with

Edison - an Investment Research Company - has taken up coverage of the Oncology Venture share

Please visit Edison to read their initiation report: link   For further information about Oncology Venture, please contact: Ulla Hald Buhl, COO and Chief IR & or Peter Buhl Jensen, CEOMobile: +45 21 60CommunicationsMobile: +45 2170 89 22E-mail: pbj@oncologyventure.com  1049uhb@oncologyventure.com About Oncology Venture Sweden AB  Oncology Venture Sweden AB is engaged in the research and development of anti-cancer drugs via its wholly owned Danish subsidiary Oncology Venture ApS. Oncology Venture has a license to use Drug

Publication of Merger Prospectus

Oncology Venture Sweden AB (”Oncology Venture”) hereby publishes prospectus regarding the planned merger between OV and Medical Prognosis Institute A/S. The prospectus is available on Oncology Venture’s website (www.oncologyventure.com).For further information, please contact Ulla Hald Buhl, COO and       Or      Peter Buhl Jensen, CEOChief IR & Communications      Mobile: +45 21 60 89 22Mobile: +45 2170 1049      E-mail: pbj@oncologyventure.comE-mail: uhb@oncologyventure.com About Oncology Venture Sweden AB Oncology Venture Sweden

Publication of merger plan related to the merger between Oncology Venture and MPI

Oncology Venture Sweden AB (”Oncology Venture”) and Medical Prognosis Institute A/S (”MPI”), on the 9th of March 2018, announced their intention to conduct a merger of the companies. The complete merger plan is now available on Oncology Venture’s (www.oncologyventure.com) and MPI’s (www.medical-prognosis.com) respective websites. The merger plan is also available as an attachment to this press release.For further information, please contact Ulla Hald Buhl, COO and Or Peter Buhl Jensen, CEOMobile: +45 21Chief IR & 60 89 22E-mail:CommunicationsMobile: pbj@

Notice of Annual Shareholders’ Meeting in Oncology Venture Sweden AB

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. Hoersholm, Denmark, April 30, 2018 – The shareholders in Oncology Venture Sweden AB, Reg. No. 559016-3290, are hereby invited to attend the annual shareholders’ meeting (Sw. årsstämma) to be held at the offices of Setterwalls Advokatbyrå AB, Stortorget 23 in Malmö, Sweden on Wednesday 30 May 2018 at 10.00 a.m.Right to participate and notice of participation Shareholders wishing to attend the annual shareholders’ meeting must:

New date for the Annual General Meeting

Oncology Venture Sweden AB hereby announces that the new planned date for the Annual General Meeting is the 30th of May 2018. Previously communicated date was the 17th of May 2018.For further information, please contact Ulla Hald Buhl, COO and Chief IR & CommunicationsMobile: +45 2170 1049E-mail: uhb@oncologyventure.com    Or  Peter Buhl Jensen, CEOMobile: +45 21 60 89 22E-mail: pbj@oncologyventure.com  About Oncology Venture Sweden AB Oncology Venture Sweden AB is engaged in the research and development of anti-cancer drugs via its wholly owned Danish subsidiary

Claus Frisenberg buys shares in Oncology Venture and MPI

Hoersholm, Denmark – March 27th  2018   Oncology Venture Sweden AB (OV:ST) (“Oncology Venture”) and Medical Prognosis Institute (MPI.ST) (“MPI”) announces that Claus Frisenberg, CCO and CFO in Oncology Venture, has bought 3 700 shares in Oncology Venture at a price of 18,36 SEK per share and 6 300 shares in MPI at a price of 10,816 SEK per share. All shares has been bought on March 26, 2018, in the trade at AktieTorget and Nasdaq Stockholm First North, respectively.  On 9th March 2018 Oncology Venture and Medical Prognosis Institute announced plans of a merger of the companies.

Scientific journal highlights study of the DRP tool in cisplatin treatment for patients with lung cancer

Hoersholm, Denmark – March 22,  2018 – Oncology Venture Sweden AB:s (OV:ST) (“Oncology Venture” or “OV”) and Medical Prognosis Institute (MPI.ST) (“Medical Prognosis Institute” or “MPI”) announces positive study results for the diagnostic tool DRP® in lung cancer patients treated with cisplatin. The findings have been published in the scientific journal  PLOS ONE under the title “Molecular Prediction of adjuvant cisplatin efficacy in Non-small cell lung cancer – validation in two independent cohorts.”  Data from both a prospective randomized clinical trial and a Danish NSCLC patient cohort

There are no items matching the current filter
There are no more items matching the current filter
Back to top